Trials / Unknown
UnknownNCT04679506
the Efficacy and Safety of CLAE in R/R T-ALL/LBL
Clinical Observation on the Efficacy and Safety of CLAE Regimen (Cladribine + Cytarabine + Etoposide) in the Treatment of Relapsed/Refractory T- Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Peking University Third Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL.
Detailed description
This study is a prospective, open, multiple -centered, sing-arm trial. The major aim of this studies to evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL. The study will include 50 subjects to receive CLAE regimen for reinduction chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cladribine | CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2021-12-01
- Completion
- 2023-12-01
- First posted
- 2020-12-22
- Last updated
- 2020-12-22
Source: ClinicalTrials.gov record NCT04679506. Inclusion in this directory is not an endorsement.